Ahmed A. Othman
About
Ahmed A. Othman is a scholar working on Oncology, Immunology and Molecular Biology.
According to data from OpenAlex, Ahmed A. Othman has authored 91 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 21 papers in Immunology and 17 papers in Molecular Biology. Recurrent topics in Ahmed A. Othman's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Immunotherapy and Immune Responses (8 papers). Ahmed A. Othman is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Immunotherapy and Immune Responses (8 papers). Ahmed A. Othman collaborates with scholars based in United States, Egypt and United Kingdom. Ahmed A. Othman's co-authors include Sandeep Dutta, Weining Robieson, Robert Lenz, Mohamed‐Eslam F. Mohamed, Aileen L. Pangan, Mohamed Marzouk, Yili Pritchett, Heidi S. Camp, Krai Chatamra and Per Odin and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and American Journal of Psychiatry.
In The Last Decade
Ahmed A. Othman
88 papers receiving 2.7k citations
Hit Papers
Peers
Ahmed A. Othman
Katherine Dawson United States
Monika Baier United States
Thibault Moreau France
Zsolt Szabó United States
Ning Cheung Singapore
Patrick Fleming Canada
Paulus T.V.M. de Jong Netherlands
Dong Kim United States
Meng Wei China
Ryo Ogawa Japan
Citations per year, relative to Ahmed A. Othman Ahmed A. Othman (= 1×)
peers
Katherine Dawson
Countries citing papers authored by Ahmed A. Othman
Since
Specialization
Citations
This map shows the geographic impact of Ahmed A. Othman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmed A. Othman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmed A. Othman more than expected).
Fields of papers citing papers by Ahmed A. Othman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ahmed A. Othman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmed A. Othman. The network helps show where Ahmed A. Othman may publish in the future.
Co-authorship network of co-authors of Ahmed A. Othman
This figure shows the co-authorship network connecting the top 25 collaborators of Ahmed A. Othman. A scholar is included among the top collaborators of Ahmed A. Othman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmed A. Othman. Ahmed A. Othman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Younis, Islam R., Elijah J. Weber, Cara R. Nelson, et al.. (2025). Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease. The Journal of Clinical Pharmacology. 65(7). 850–859.
2.
Dauki, Anees M., Nishanthan Rajakumaraswamy, Torsten Trowe, et al.. (2024). Pharmacokinetics, pharmacodynamics, and safety of GS ‐3583, a FLT3 agonist Fc fusion protein, from single‐ascending‐dose phase I study in healthy participants. Clinical and Translational Science. 17(8). e70011–e70011.
3.
Sathe, Abhishek G., et al.. (2024). Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer. Clinical Pharmacology & Therapeutics. 117(2). 570–578.
4.
Younis, Islam R., Cara Nelson, Elijah J. Weber, et al.. (2024). Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. The Journal of Clinical Pharmacology. 64(7). 878–886.
5.
Sathe, Abhishek G., Indrajeet Singh, Paul M. Diderichsen, et al.. (2024). Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical Pharmacokinetics. 63(5). 669–681.
6.
Younis, Islam R., Fan Wang, & Ahmed A. Othman. (2024). Feasibility of Using Population Pharmacokinetics‐Based Virtual Control Groups in Organ Impairment Studies. The Journal of Clinical Pharmacology. 64(6). 713–718.
7.
Odegard, Jared, Ahmed A. Othman, Kai-Wen Lin, et al.. (2024). Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(4). e008547–e008547.
8.
Tolcher, Anthony W., Michael S. Gordon, Kathleen M. Mahoney, et al.. (2023). Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11(2). e005267–e005267.
9.
Younis, Islam R., Cara Nelson, Brian J. Kirby, et al.. (2023). Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Clinical Pharmacokinetics. 62(4). 609–621.
10.
Harky, Amer, Ahmed A. Othman, Matthew Shaw, et al.. (2021). Outcomes of acute type A aortic dissection repair: Daytime versus nighttime. JTCVS Open. 7. 12–20.
11.
Harky, Amer, et al.. (2021). The life in their years versus the years in their life. Journal of Thoracic and Cardiovascular Surgery. 161(5). e361–e362.
12.
Harky, Amer, et al.. (2020). Factors Affecting Outcomes in Acute Type A Aortic Dissection: A Systematic Review. Heart Lung and Circulation. 29(11). 1668–1681.
13.
Guttman‐Yassky, Emma, Diamant Thaçi, Aileen L. Pangan, et al.. (2019). Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 145(3). 877–884.
14.
Bain, Earle, Laura Shafner, David P. Walling, et al.. (2017). Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mhealth and uhealth. 5(2). e18–e18.
15.
Florian, Hana, Andreas Meier, Serge Gauthier, et al.. (2016). Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Alzheimer s Disease. 51(4). 1237–1247.
16.
Diao, Lei, Yaming Hang, Ahmed A. Othman, Ivan Nestorov, & Jonathan Q. Tran. (2016). Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials. Clinical Pharmacokinetics. 55(8). 943–955.
17.
Gault, Laura M., Robert Lenz, Craig Ritchie, et al.. (2016). ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimer s Research & Therapy. 8(1). 44–44.
18.
Tran, Jonathan Q., et al.. (2015). Daclizumab High-Yield Process (DAC HYP) has no Effect on Activity of the Cytochrome P450 (CYP) Enzymes: Results of a Drug Cocktail Interaction Study in Subjects with Multiple Sclerosis (MS) (P1.148). Neurology. 84(14_supplement).
19.
Nyholm, Dag, Per Odin, Anders Johansson, et al.. (2012). Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal. 15(2). 316–323.
20.
Othman, Ahmed A., Amy Hauck Newman, & Natalie D. Eddington. (2007). Applicability of the Dopamine and Rate Hypotheses in Explaining the Differences in Behavioral Pharmacology of the Chloro-Benztropine Analogs: Studies Conducted Using Intracerebral Microdialysis and Population Pharmacodynamic Modeling. Journal of Pharmacology and Experimental Therapeutics. 322(2). 760–769.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Katherine Dawson Breakdown of academic impact, for papers by Monika Baier Breakdown of academic impact, for papers by Thibault Moreau Breakdown of academic impact, for papers by Zsolt Szabó Breakdown of academic impact, for papers by Ning Cheung Breakdown of academic impact, for papers by Patrick Fleming Breakdown of academic impact, for papers by Paulus T.V.M. de Jong Breakdown of academic impact, for papers by Dong Kim Breakdown of academic impact, for papers by Meng Wei Breakdown of academic impact, for papers by Ryo Ogawa